Jazz Pharmaceuticals (JAZZ)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$246.81-0.31%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · JAZZ
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | 4,601.3 | 4,267.6 | 4,069.0 | 3,834.2 | 3,659.4 | 3,094.2 | 2,363.6 | 2,161.8 | 1,890.9 | 1,618.7 | 1,488.0 | 1,324.8 | 1,172.9 | 872.4 | 586.0 | 272.3 |
| Total Revenues | — | — | — | — | — | — | — | — | — | 1,618.7 | 1,488.0 | 1,324.8 | 1,172.9 | 872.4 | 586.0 | 272.3 |
| Operating Expenses & Income | ||||||||||||||||
| Selling, General & Admin | 1,678.8 | 1,809.3 | 1,385.3 | 1,343.1 | 1,417.0 | 1,451.7 | 854.2 | 736.9 | 683.5 | 544.2 | 502.9 | 449.1 | 406.1 | 304.3 | 223.9 | 108.9 |
| R&D Expenses | — | — | — | — | — | — | — | 299.7 | 226.6 | 198.4 | 162.3 | 135.3 | 85.2 | 41.6 | 20.5 | 14.1 |
| Operating Income | 896.9 | (430.2) | 716.6 | 578.6 | (65.5) | 170.3 | 378.1 | 532.4 | 614.8 | 528.8 | 591.7 | 508.2 | 195.6 | 340.3 | 197.8 | 127.8 |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 1.7 |
| Interest & Investment Income | 87.8 | 85.8 | 106.3 | 65.1 | 11.5 | 1.8 | 11.1 | 20.5 | — | — | — | — | — | — | — | 0.1 |
| Net Interest Expenses | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 1.6 |
| Asset Writedown | — | — | — | 0.0 | 133.6 | 0.0 | 136.1 | 0.0 | 42.9 | 0.0 | 0.0 | 31.5 | 39.4 | — | — | — |
| EBT, Incl. Unusual Items | 727.7 | (627.9) | 470.4 | 297.9 | (372.8) | (112.8) | 275.1 | 454.3 | 529.5 | 441.1 | 532.4 | 435.9 | 151.6 | 308.0 | 177.4 | — |
| Income Tax Expense | (213.2) | (272.4) | (91.4) | (119.9) | (158.6) | 216.1 | 33.5 | (73.2) | 80.2 | (47.7) | 135.2 | 106.4 | 94.2 | 91.6 | (83.8) | 0.0 |
| Earnings from Continuing Operations | — | — | — | — | — | — | — | — | — | — | — | — | 57.3 | — | — | — |
| Net Income | ||||||||||||||||
| Minority Interest | — | — | — | — | — | — | — | — | — | 0.0 | 0.0 | (0.0) | (1.1) | — | — | — |
| Net Income | 940.8 | (356.1) | 560.1 | 414.8 | (224.1) | (329.7) | 238.6 | 523.4 | 447.1 | 487.8 | 396.8 | 329.5 | 58.4 | 216.3 | 288.6 | 125.0 |
| Per Share | ||||||||||||||||
| Basic EPS | 14.89 | (5.84) | 9.06 | 6.55 | (3.58) | (5.52) | 4.28 | 9.22 | 7.45 | 8.13 | 6.56 | 5.38 | 0.98 | 3.71 | 5.09 | 3.01 |
| Diluted EPS | 13.56 | (5.84) | 8.65 | 6.10 | (3.58) | (5.52) | 4.22 | 9.09 | 7.30 | 7.96 | 6.41 | 5.23 | 0.93 | 3.51 | 4.79 | 2.67 |
| Revenue per Share | 66.30 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 63.2 | 61.0 | 61.8 | 63.3 | 62.5 | 59.7 | 55.7 | 56.7 | 60.0 | 60.0 | 60.5 | 61.2 | 59.7 | 58.3 | 56.6 | 41.5 |
| Diluted Weighted Avg Shares | 69.4 | 61.0 | 66.0 | 72.1 | 62.5 | 59.7 | 56.5 | 57.6 | 61.2 | 61.3 | 61.9 | 63.0 | 62.6 | 61.6 | 60.2 | 46.8 |
| Supplemental | ||||||||||||||||
| EBITDA | — | (388.6) | 749.4 | 609.0 | (35.2) | 197.0 | 396.8 | 547.7 | 630.0 | 541.9 | — | — | — | — | — | — |
| EBIT | 896.9 | (430.2) | 716.6 | 578.6 | (65.5) | 170.3 | 378.1 | 532.4 | 614.8 | 528.8 | 591.7 | 508.2 | 195.6 | 340.3 | 197.8 | 127.8 |
| Effective Tax Rate | -29.3% | — | — | -40.2% | 42.6% | -191.5% | 12.2% | -16.1% | 15.1% | -10.8% | 25.4% | 24.4% | 62.2% | 29.8% | -47.2% | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.